Supernus (NASDAQ: SUPN) CMO Jonathan Rubin awarded options and RSUs

Rhea-AI Filing Summary

SUPERNUS PHARMACEUTICALS, INC. senior vice president and chief medical officer Jonathan Rubin received new equity awards. On February 18, 2026, he was granted an employee stock option for 13,500 shares and 3,000 restricted stock units, both at no exercise cost per the filing.

The option vests in four equal annual installments starting February 18, 2027. Each restricted stock unit converts into one share of common stock and also vests in four equal annual installments beginning on that date. Following these awards, Rubin directly holds 11,284 shares of common stock, including 269 acquired through the employee stock purchase plan.

Insider Trade Summary

3 transactions reported

Mixed 3 txns

Insider Rubin Jonathan

Role SVP, Chief Medical Officer

Type	Security	Shares	Price	Value
Grant/Award	Employee Stock Option (Right to Buy)	13,500	$0.00	--
Grant/Award	Restricted Stock Unit	3,000	$0.00	--
holding	Common Stock	--	--	--

Holdings After Transaction: Employee Stock Option (Right to Buy) — 13,500 shares (Direct); Restricted Stock Unit — 3,000 shares (Direct); Common Stock — 11,284 shares (Direct)

Footnotes (1)

1. Includes an aggregate of 269 shares acquired by the Reporting Person through the Issuer's Employee Stock Purchase Plan. The option vests in four equal annual installments beginning on February 18, 2027. Each restricted stock unit represents the right to receive one share of Supernus common stock upon vesting. These restricted stock units are settled in common stock upon vesting, which occurs in four equal annual installments, beginning on February 18, 2027.

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Rubin Jonathan

(Last) (First) (Middle)

C/O SUPERNUS PHARMACEUTICALS, INC.,

9715 KEY WEST AVENUE

(Street)

ROCKVILLE MD 20850

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
SUPERNUS PHARMACEUTICALS, INC. [ SUPN ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	SVP, Chief Medical Officer

3. Date of Earliest Transaction (Month/Day/Year)
02/18/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock								11,284(1)	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Employee Stock Option (Right to Buy)	$50.2	02/18/2026		A		13,500		(2)	02/18/2036	Common Stock	13,500	$0	13,500	D
Restricted Stock Unit	(3)	02/18/2026		A		3,000		(4)	(4)	Common Stock	3,000	$0	3,000	D

Explanation of Responses:

1. Includes an aggregate of 269 shares acquired by the Reporting Person through the Issuer's Employee Stock Purchase Plan.

2. The option vests in four equal annual installments beginning on February 18, 2027.

3. Each restricted stock unit represents the right to receive one share of Supernus common stock upon vesting.

4. These restricted stock units are settled in common stock upon vesting, which occurs in four equal annual installments, beginning on February 18, 2027.

Remarks:

	/s/ Timothy C. Dec, as attorney-in-fact	02/20/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What equity awards did SUPN executive Jonathan Rubin receive?

Jonathan Rubin received an option for 13,500 shares and 3,000 restricted stock units. Both awards were granted at a stated price of $0.0000 per share and represent additional long-term equity incentives tied to Supernus common stock.

When do Jonathan Rubin’s new Supernus stock options vest?

Rubin’s 13,500-share option vests in four equal annual installments starting February 18, 2027. This structure spreads the vesting over four years, encouraging longer-term alignment with Supernus’s performance and his continued service as chief medical officer.

How are Jonathan Rubin’s Supernus RSUs structured and settled?

Rubin’s 3,000 restricted stock units each represent the right to receive one share of Supernus common stock. They vest in four equal annual installments beginning February 18, 2027 and are settled in common stock upon vesting, adding to his potential share ownership.

How many Supernus common shares does Jonathan Rubin hold after these awards?

After the reported awards, Rubin directly holds 11,284 shares of Supernus common stock. This figure includes 269 shares acquired through the company’s Employee Stock Purchase Plan, as disclosed in the footnotes to the insider ownership report.

Does the Supernus Form 4 show any stock sales by Jonathan Rubin?

The Form 4 only reports acquisitions: an option grant and restricted stock units. There are no sales transactions reported in this filing, and the transaction summary shows two acquisitions with no disposals or net selling activity for the period covered.

What role does Jonathan Rubin hold at Supernus Pharmaceuticals (SUPN)?

Jonathan Rubin serves as senior vice president and chief medical officer at Supernus Pharmaceuticals. His Form 4 filing reflects equity compensation tied to this leadership role, including an employee stock option grant and restricted stock units awarded on February 18, 2026.